May 13, 2025 12:22 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India struck Malir Cantonment in Karachi: IAF's big revelation on Operation Sindoor | Nuclear blackmailing will not be tolerated, Operation Sindoor not over: PM Modi in address to nation | Military bases, equipment, systems operational, ready for next mission if required: Armed Forces on Operation Sindoor | India's cricket icon Virat Kohli retires from Test cricket | Secretary of State Marco Rubio says US position on Russia-Ukraine war remains on reaching 'immediate ceasefire' | Trade war de-escalation: US, China decide to roll back most tariffs for 90 days | India and Pakistan agreed to stop military actions: Govt confirms Trump's ceasefire claim | India, Pakistan have reached full and immediate ceasefire: Donald Trump announces on Truth Social | 'Frivolous allegation': India dismisses Pakistan's 'Indian missiles hit Afghanistan' disinformation | India opposes IMF's proposal to extend fresh loans to Pakistan, abstains from voting
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm
PM Modi on Budget 2024 Jul 23, 2024, at 09:30 pm